Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of ZX-7101A (Seloxavir marboxil) in healthy Chinese males
NCT05720091Phase 1Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Seloxavir marboxil in influenza, sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Cumulative recovery of total radioactive material in urine and feces, Cmax of total radioactivity in plasma and 1 more. Started Feb 2023; status: completed.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05720091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720091.